Latest & greatest articles for albuterol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on albuterol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on albuterol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for albuterol

1. Inhaled Salbutamol Shortage – Mitigation Strategy for Asthma

Inhaled Salbutamol Shortage – Mitigation Strategy for Asthma CTS Guidance on Salbutamol Shortage – April 13,2020 1 Inhaled Salbutamol Shortage – Mitigation Strategy for Asthma April 13, 2020 Background 1) Health Canada and the pharmaceutical industry have identified that there was a three-fold increase in the demand for salbutamol inhalers in the first 3 weeks of March 2020. 2) This has resulted in a Tier 3 shortage, which by definition is “a situation when a manufacturer/importer is unable (...) to meet demand for the drug. A tier 3 shortage is a shortage with the greatest potential impact on the Canadian drug supply and healthcare systems by virtue of availability of alternate supplies, ingredients, or therapies.” 3) Restrictions have been put in place by wholesalers and distributors to limit the supply of salbutamol which means that most patients will receive only one salbutamol inhaler or a one-month supply at a time. 4) It is possible that the surge in demand relates to individuals

2020 Canadian Thoracic Society

2. Inhaled Salbutamol Shortage – Mitigation Strategy for COPD

Inhaled Salbutamol Shortage – Mitigation Strategy for COPD CTS Guidance on Salbutamol Shortage - April 13, 2020 1 Inhaled Salbutamol Shortage – Mitigation Strategy for COPD April 13, 2020 Background 1) Health Canada and the pharmaceutical industry have identified that there was a three-fold increase in the demand for salbutamol inhalers in the first 3 weeks of March 2020. 2) This has resulted in a Tier 3 shortage, which by definition is “a situation when a manufacturer/importer is unable (...) to meet demand for the drug. A tier 3 shortage is a shortage with the greatest potential impact on the Canadian drug supply and healthcare systems by virtue of availability of alternate supplies, ingredients, or therapies.” 3) Restrictions have been put in place by wholesalers and distributors to limit the supply of salbutamol which means that most patients will receive only one salbutamol inhaler or a one month supply at a time . 4) It is possible that the surge in demand relates to individuals

2020 Canadian Thoracic Society

3. Efficacy of salbutamol in the treatment of infants with bronchiolitis: A meta-analysis of 13 studies. (Full text)

Efficacy of salbutamol in the treatment of infants with bronchiolitis: A meta-analysis of 13 studies. To systematically evaluate the clinical efficacy of salbutamol treatment in infants with bronchiolitis.A systematic review and meta-analysis of randomized controlled trials (RCTs) investigating the use of salbutamol in infants with bronchiolitis was performed. The Cochrane Risk of Bias Assessment Tool was used to evaluate the quality of RCTs. Data were extracted and meta-analyzed using STATA (...) version 12.0 (StataCorp, College Station, TX).Thirteen RCTs, including a total of 977 participants, were assessed in the present meta-analysis. Results indicated that salbutamol therapy for bronchiolitis in infants led to an increase in respiratory rate (weighted mean difference [WMD] 2.26 [95% confidence interval {CI} 0.36-4.16]) and higher heart rate (WMD 12.15 [95% CI 9.24-15.07]). However, as a selective β2-agonist, salbutamol did not improve the clinical severity score of infants

2020 Medicine PubMed abstract

4. The Influence of Beta-2 Adrenergic Receptor Gene Polymorphisms on Albuterol Therapy for Patients With Asthma: Protocol for a Systematic Review and Meta-Analysis. (Full text)

The Influence of Beta-2 Adrenergic Receptor Gene Polymorphisms on Albuterol Therapy for Patients With Asthma: Protocol for a Systematic Review and Meta-Analysis. Albuterol is one of the most frequently used medications in clinical practice and seeing varying responses to albuterol between individuals is not uncommon. Multiple studies have been conducted to investigate the associations of differing responses due to albuterol, particularly with regards to the two nonsynonymous single nucleotide (...) polymorphisms (SNPs) at positions 16 (Arg16Gly: substitution of arginine to glycine at position 16; rs1042713) and 27 (Glu27Gln: substitution of glutamic acid to glutamine at position 27; rs1042714) on the β-2 adrenergic receptor (ADRB2) gene. However, the directions of the correlations are conflicting.The objective of this systematic review and meta-analysis is to assess the effect of the two SNPs on the ADRB2 gene, in terms of the responses that present in asthmatic patients shortly after albuterol

2019 JMIR Research Protocols PubMed abstract

5. Salbutamol Administration via Nebulizer Versus Metered-Dose Inhalers: Clinical Effectiveness and Cost-Effectiveness

Salbutamol Administration via Nebulizer Versus Metered-Dose Inhalers: Clinical Effectiveness and Cost-Effectiveness Salbutamol Administration via Nebulizer Versus Metered-Dose Inhalers: Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Salbutamol Administration via Nebulizer Versus Metered-Dose Inhalers: Clinical Effectiveness and Cost-Effectiveness Salbutamol Administration via Nebulizer Versus Metered-Dose Inhalers: Clinical Effectiveness and Cost (...) -Effectiveness Last updated: August 2, 2019 Project Number: RB1367-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of administering salbutamol via nebulizer versus metered dose inhalers in pre-hospital or emergency settings? What is the cost-effectiveness of administering salbutamol via nebulizer versus metered dose inhalers in pre-hospital or emergency settings? Key Message One randomized controlled trial and one non

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

6. Effect of Albuterol Premedication vs Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: The REACT Randomized Clinical Trial (Abstract)

Effect of Albuterol Premedication vs Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: The REACT Randomized Clinical Trial Tonsillectomy is a common pediatric procedure for the treatment of sleep-disordered breathing and chronic tonsillitis. Up to half of children having this procedure experience a perioperative respiratory adverse event.To determine whether inhaled albuterol sulfate (salbutamol sulfate) premedication decreases the risk (...) was conducted between July 15, 2014, and May 18, 2017.Participants were randomized to receive either albuterol (2 actuations, 200 μg) or placebo before their surgery.Occurrence of perioperative respiratory adverse events (bronchospasm, laryngospasm, airway obstruction, desaturation, coughing, and stridor) until discharge from the postanesthesia care unit.Of 484 randomized children (median [range] age, 5.6 [1.6-8.9] years; 285 [58.9%] boys), 479 data sets were available for intention-to-treat analysis

2019 EvidenceUpdates

7. Albuterol

have questions please contact us via jon.brassey@tripdatabase.com Top results for albuterol 1. Clinical comparison of fenoterol and albuterol administered by inhalation. A double-blind study. 344007 1978 05 17 1978 05 17 2013 11 21 0012-3692 73 3 1978 Mar Chest Chest Clinical comparison of fenoterol and albuterol administered by inhalation. A double-blind study. 348-51 The effects of inhaling 0.4 mg of fenoterol hydrobromide (Berotec), 0.2 mg of albuterol (salbutamol), or placebo were compared (...) of Cardiogenic Pulmonary Edema. Congestive Heart Failure Drug: Albuterol Drug: Normal Saline Phase 2 Phase 3 Study Type: Interventional 2010 8. A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol /Salbutamol and Ipratropium A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol /Salbutamol and Ipratropium - Full Text View - ClinicalTrials.gov A service of the U.S. National Institutes of Health Example: "Heart attack" AND "Los Angeles

2018 Trip Latest and Greatest

8. Effect of On-Demand vs Routine Nebulization of Acetylcysteine With Salbutamol on Ventilator-Free Days in Intensive Care Unit Patients Receiving Invasive Ventilation: A Randomized Clinical Trial. (Full text)

Effect of On-Demand vs Routine Nebulization of Acetylcysteine With Salbutamol on Ventilator-Free Days in Intensive Care Unit Patients Receiving Invasive Ventilation: A Randomized Clinical Trial. It remains uncertain whether nebulization of mucolytics with bronchodilators should be applied for clinical indication or preventively in intensive care unit (ICU) patients receiving invasive ventilation.To determine if a strategy that uses nebulization for clinical indication (on-demand) is noninferior (...) to one that uses preventive (routine) nebulization.Randomized clinical trial enrolling adult patients expected to need invasive ventilation for more than 24 hours at 7 ICUs in the Netherlands.On-demand nebulization of acetylcysteine or salbutamol (based on strict clinical indications, n = 471) or routine nebulization of acetylcysteine with salbutamol (every 6 hours until end of invasive ventilation, n = 473).The primary outcome was the number of ventilator-free days at day 28, with a noninferiority

2018 JAMA Controlled trial quality: predicted high PubMed abstract

9. A Model-Based Meta-Analysis Evaluating Gender Differences on Blood Flow Responses to Brachial Artery Infusions of Acetylcholine, Albuterol, ATP, Bradykinin, Estradiol, Glyceryl Trinitrate, L-NMMA, Nevibolol, Norepinephrine, Sodium Nitroprusside, Substance (Full text)

A Model-Based Meta-Analysis Evaluating Gender Differences on Blood Flow Responses to Brachial Artery Infusions of Acetylcholine, Albuterol, ATP, Bradykinin, Estradiol, Glyceryl Trinitrate, L-NMMA, Nevibolol, Norepinephrine, Sodium Nitroprusside, Substance Numerous studies have emerged over the course of several decades describing the properties of drugs eliciting vasodilatory or vasoconstrictor responses in the human vasculature. During drug development, decisions to move forward with testing (...) with a new chemical entity are very costly. To fund or not to fund development, go or no-go, decisions are often limited by efficacy comparisons with the current products on the market. The primary aim of this paper is to use dose-response modeling and simulations to quantify differences in blood flow to Acetylcholine, Albuterol, ATP, Bradykinin, 17β-Estradiol, Glyceryl Trinitrate, L-NMMA, Nevibolol, Norepinephrine, Sodium Nitroprusside, Substance P, and Verapamil.Five studies were identified

2017 MEDtube science PubMed abstract

10. Salbutamol for transient tachypnea of the newborn. (Abstract)

Salbutamol for transient tachypnea of the newborn. Transient tachypnea of the newborn is characterized by tachypnea and signs of respiratory distress. Transient tachypnea typically appears within the first two hours of life in term and late preterm newborns. Although transient tachypnea of the newborn is usually a self limited condition, it is associated with wheezing syndromes in late childhood. The rationale for the use of salbutamol (albuterol) for transient tachypnea of the newborn is based (...) on studies showing that β-agonists can accelerate the rate of alveolar fluid clearance.To assess whether salbutamol compared to placebo, no treatment or any other drugs administered to treat transient tachypnea of the newborn, is effective and safe in the treatment of transient tachypnea of the newborn in infants born at 34 weeks' gestational age or more.We searched the Cochrane Central Register of Controlled Trials (CENTRAL, 2016, Issue 3), MEDLINE (1996 to March 2016), EMBASE (1980 to March 2016

2016 Cochrane

11. Albuterol in the treatment of acute respiratory distress syndrome: A meta-analysis of randomized controlled trials. (Full text)

Albuterol in the treatment of acute respiratory distress syndrome: A meta-analysis of randomized controlled trials. This meta-analysis of randomized controlled trials aimed to systematically evaluate the value of albuterol in the treatment of patients with acute respiratory distress syndrome (ARDS).Randomized controlled trials on albuterol treatment of ARDS from its inception to October 2014 were searched systematically. The databases searched included: PubMed, Ovid EMBASE, Ovid Cochrane, CNKI (...) , WANFANG and VIP. The trials were screened according to the pre-designed inclusion and exclusion criteria. We performed a systematic review and meta-analysis of the randomized controlled trials (RCTs) on albuterol treatment, attempting to improve outcomes, i.e. lowering the 28-day mortality and ventilator-free days.Three RCTs involving 646 patients met the inclusion criteria. There was no significant decrease in the 28-day mortality (risk difference=0.09; P=0.07, P for heterogeneity=0.22, I (2)=33

2015 World journal of emergency medicine PubMed abstract

12. Beta-Agonist Lung injury TrIal-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome

Beta-Agonist Lung injury TrIal-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome Beta-Agonist Lung injury TrIal-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome Beta-Agonist Lung (...) injury TrIal-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome Gates S, Perkins G, Lamb S, Kelly C, Thickett D, Young J, McAuley D, Snaith C, McCabe C, Hulme C, Gao Smith F Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been

2013 Health Technology Assessment (HTA) Database.

13. Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysis. (Abstract)

Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysis. Conventional albuterol is a racemic mixture of (S)-albuterol and (R)-albuterol (levalbuterol). Levalbuterol is therapeutically active component of albuterol whereas (S)-albuterol is considered inert with some unwanted effects.To evaluate efficacy and safety of levalbuterol versus albuterol in acute asthma.Systematic review and meta-analysis.Pubmed and Cochrane databases. TRIAL ELIGIBILITY CRITERIA (...) , PARTICIPANTS, AND INTERVENTIONS: Randomized control trials comparing levalbuterol versus albuterol for acute asthma in all age groups. DATA EXTRACTION AND RESULT SYNTHESIS: Two authors extracted data independently. Meta-analyses were performed using Review Manager Software.Seven trials including a total of 1625 participants fulfilled the eligibility criteria. Respiratory rate, oxygen saturation, and percentage change in FEV1 and clinical asthma score were not significantly different between the groups

2013 Pulmonary Pharmacology & Therapeutics

14. Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray

Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray Drug Approval Package: Combivent Respimat (ipratropium bromide and albuterol) NDA #021747 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray Company: Boehringer Ingelheim Pharmaceutical, Inc. Application No.: 021747 Approval Date: 10/07/2011 Persons with disabilities having problems accessing the PDF files below may

2011 FDA - Drug Approval Package

15. Randomised controlled trial: In children and adolescents with mild persistent asthma, daily beclomethasone reduces treatment failure compared with rescue beclomethasone plus albuterol

Randomised controlled trial: In children and adolescents with mild persistent asthma, daily beclomethasone reduces treatment failure compared with rescue beclomethasone plus albuterol In children and adolescents with mild persistent asthma, daily beclomethasone reduces treatment failure compared with rescue beclomethasone plus albuterol | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via (...) asthma, daily beclomethasone reduces treatment failure compared with rescue beclomethasone plus albuterol Article Text Therapeutics Randomised controlled trial In children and adolescents with mild persistent asthma, daily beclomethasone reduces treatment failure compared with rescue beclomethasone plus albuterol Tom Kovesi Statistics from Altmetric.com Commentary on: Martinez FD , Chinchilli VM , Morgan WJ , et al . Use of beclomethasone dipropionate as rescue treatment for children with mild

2011 Evidence-Based Medicine

16. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. (Full text)

Active albuterol or placebo, sham acupuncture, or no intervention in asthma. In prospective experimental studies in patients with asthma, it is difficult to determine whether responses to placebo differ from the natural course of physiological changes that occur without any intervention. We compared the effects of a bronchodilator, two placebo interventions, and no intervention on outcomes in patients with asthma.In a double-blind, crossover pilot study, we randomly assigned 46 patients (...) with asthma to active treatment with an albuterol inhaler, a placebo inhaler, sham acupuncture, or no intervention. Using a block design, we administered one each of these four interventions in random order during four sequential visits (3 to 7 days apart); this procedure was repeated in two more blocks of visits (for a total of 12 visits by each patient). At each visit, spirometry was performed repeatedly over a period of 2 hours. Maximum forced expiratory volume in 1 second (FEV(1)) was measured

2011 NEJM Controlled trial quality: uncertain PubMed abstract

17. Should I use 2.5mg or 5mg Nebulised Salbutamol in Acute Exacerbations of COPD?

benefit (1 mg/ml: 20×2.5 ml (2.5 mg) @ £1.99 and 2 mg/ml: 20×2.5 ml (5 mg) @ £3.98). Clinical Bottom Line Patients admitted with acute exacerbations of COPD requiring nebulised therapy should be considered for 2.5 mg nebulised salbutamol in place of 5 mg. References Nair S. A Randomised Controlled Trial to Assess the Optimal Dose and Effect Of Nebulised Albuterol in Acute Exacerbations of COPD. Chest 2005;128;48-54. (...) Should I use 2.5mg or 5mg Nebulised Salbutamol in Acute Exacerbations of COPD? BestBets: Should I use 2.5mg or 5mg Nebulised Salbutamol in Acute Exacerbations of COPD? Should I use 2.5mg or 5mg Nebulised Salbutamol in Acute Exacerbations of COPD? Report By: Sandeep Rahul Kusre - Senior House Officer Search checked by Jonathan Costello - Consultant A&E Institution: Royal Free Hospital Date Submitted: 4th April 2009 Date Completed: 21st October 2010 Last Modified: 21st October 2010 Status: Green

2010 BestBETS

18. Nebulised salbutamol or nebulised adrenaline for wheeze in anaphylaxis

Nebulised salbutamol or nebulised adrenaline for wheeze in anaphylaxis BestBets: Nebulised salbutamol or nebulised adrenaline for wheeze in anaphylaxis Nebulised salbutamol or nebulised adrenaline for wheeze in anaphylaxis Report By: Deepak Doshi - Specialist Registrar in Emergency Medicine Search checked by Bernard A Foëx - Consultant in Emergency Medicine and Critical Care Institution: Manchester Royal Infirmary Date Submitted: 2nd April 2007 Date Completed: 14th October 2009 Last Modified (...) : 1st September 2009 Status: Green (complete) Three Part Question In [patients with anaphylaxis] is [nebulised salbutamol better than nebulised adrenaline] at [reducing wheeze]? Clinical Scenario A 33 year school teacher arrives in the Emergency Department following a trip to the local botanical gardens. She has breathing difficulty with extensive expiratory wheeze and a florrid urticarial rash. She was given salbutamol by nebulizer in the ambulance. She continued to wheeze in the Emergency

2009 BestBETS

19. Periodic salbutamol in facioscapulohumeral muscular dystrophy: a randomized controlled trial (Abstract)

Periodic salbutamol in facioscapulohumeral muscular dystrophy: a randomized controlled trial To evaluate the effects on muscle strength of salbutamol administered for 6 months using a periodic regimen in patients presenting with facioscapulohumeral muscular dystrophy (FSHD).Placebo-controlled double-blind randomized study.Three clinical centers involved in neuromuscular disorders.Ambulatory patients (N=112), 56 per group, with genetically confirmed FSHD, age 18 to 60 years.Salbutamol (sustained (...) released formulation) administered orally at a daily dose of 16 mg using a periodic dosage regimen (3 wks on, 1 wk off).Muscle strength was assessed with quantitative muscle testing (QMT), manual muscle testing (MMT), and timed motor tests. Patients were evaluated at baseline, and 3 and 6 months later. Plasma drug assays were carried out at each visit.There was no significant change with periodic use of salbutamol in the total composite QMT z-score, MMT score, or timed motor tests. Salbutamol was well

2009 EvidenceUpdates Controlled trial quality: predicted high

20. Is nebulised salbutamol indicated in bronchiolitis?

of nebulised salbutamol in patients with bronchiolitis. References Schuh S, Canny G, Reismann JJ, Kerem E, Bentur L, Petric M, Levison H. Nebulised albuterol in acute bronchiolitis. Journal of Pediatrics. 1990;117(4):633-637. Klassen TP, Rowe PC, Sutcliffe T, Ropp LJ, McDowell IW, Li MM. Randomised trial of salbutamol in acute bronchiolitis. The Journal of Pediatrics. 1991;118(5):807-811. Gadomski AM, Aref GH, EL Din OB, EL Sawy IH, Khallaf N, Black RE. Oral versus nebulised albuterol in the management (...) of bronchiolitis. Singapore Medical Journal. 1997;38(8):326-328. Dobson JV, Stephen -Groff SM, McMahon SR, Stemmler MM, Brallier SL, Bay C. The use of albuterol in hospitalised infants with bronchiolitis. Pediatrics. 1998;101(3 Pt 1):361-368. Ho L, Collis G, Landau LI, Le Souf PN. Effect of salbutamol on oxygen saturation in bronchiolitis. Archives of Disease in Childhood. 1991;66(9):1061-1064. Wang EE, Milner R, Allen U, Maj H. Bronchodilators for treatment of mild bronchiolitis : a factorial randomised trial

2009 BestBETS